NGeneBio Co

NGeneBio Co EBITDA Margin

The EBITDA Margin of NGeneBio Co (354200.KQ) as of Nov 17, 2026 is -38.97 %. In the previous year, EBITDA Margin was -244.72 % — a change of -84.08% (higher).

EBITDA Margin

-38.97 %

YoY

-84.08%

Last updated:

EBITDA Margin of NGeneBio Co is 2025 -38.97 % . EBITDA Margin of NGeneBio Co was 2024 -244.72 % . It decreases by -84.08% higher compared to the previous year.

The NGeneBio Co EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
-235.76 KRW
Jan 1, 2019
-256.33 KRW
Jan 1, 2020
-233.96 KRW
Jan 1, 2021
-112.40 KRW
Jan 1, 2022
-72.16 KRW
Jan 1, 2023
-294.54 KRW
Jan 1, 2024
-244.72 KRW
Jan 1, 2025
-38.97 KRW
The NGeneBio Co EBITDA Margin history
YEAREBITDA MarginYoY
-38.97 %-84.08%
-244.72 %-16.91%
-294.54 %+308.18%
-72.16 %-35.80%
-112.40 %-51.96%
-233.96 %-8.73%
-256.33 %+8.72%
-235.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NGeneBio Co Stock analysis

What does NGeneBio Co do? NGeneBio Co., Ltd. generates revenue through the development and sale of diagnostic products for cancer-related genetic testing. The company offers BRCAaccuTest for hereditary breast and ovarian cancer, HEMEaccuTest for blood cancer gene testing including leukemia and lymphoma, and SOLIDaccuTest for solid cancer tissues like lung and colon cancer. Additional products include HLAaccuTest for bone marrow transplantation antigen testing, ONCOaccuPanel for large-capacity solid cancer diagnosis, and HEREDaccuTest for rare disease diagnosis. The firm also provides direct-to-consumer genetic testing and personalized healthcare services, targeting healthcare providers, hospitals, and individual consumers seeking genetic insights. The company's product portfolio serves medical institutions and patients requiring precise genetic diagnostics. HEMEaccuTest specifically addresses blood cancer types such as leukemia and lymphoma, while SOLIDaccuTest covers common solid cancers including lung and stomach cancer. ONCOaccuPanel supports comprehensive solid cancer diagnosis, and HEREDaccuTest caters to rare disease diagnostics. These products are sold to healthcare facilities and offered directly to consumers through DTC services. NGeneBio's revenue streams include sales of diagnostic kits and services, with a focus on cancer-related genetic testing. The BRCAaccuTest, HEMEaccuTest, and SOLIDaccuTest products are central to its business, targeting both clinical and direct consumer markets. Personalized healthcare services complement the product offerings, enhancing customer engagement and recurring revenue opportunities. NGeneBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NGeneBio Co stock

EBITDA Margin of NGeneBio Co is -38.97 % in 2025.

EBITDA Margin of NGeneBio Co changed from -244.72 % to -38.97 %, representing a -84.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin NGeneBio Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's NGeneBio Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — NGeneBio Co

All Key Metrics — NGeneBio Co